Amoeba SA

Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
  • TickerAMEBA
  • ISINFR0011051598
  • ExchangeEuronext Paris
  • SectorChemicals
  • CountryFrance

Analysts

Pierre-Antoine Chazal

Green tech & Smart energy: End of coverage

Green tech & Smart energy End of coverage

Pierre-Antoine Chazal

Amoéba: H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval (

Amoéba: (CORPORATE, Fair Value EUR13 (+192%)) H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the company to continue its activities until the end of August 2019. All eyes remain on the potential US appro...

1 director sold

A director at Amoeba sold 52,256 shares at 6.420EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Pierre-Antoine Chazal

Green tech & Smart energy: End of coverage

Green tech & Smart energy End of coverage

Pierre-Antoine Chazal

Amoéba: H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval (

Amoéba: (CORPORATE, Fair Value EUR13 (+192%)) H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the company to continue its activities until the end of August 2019. All eyes remain on the potential US appro...

1 director sold

A director at Amoeba sold 52,256 shares at 6.420EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch